$2.47 Billion is the total value of Palo Alto Investors LP's 36 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 5.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ABMD | Sell | ABIOMED INC | $318,835,000 | -12.5% | 708,917 | -20.4% | 12.89% | -11.4% |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $247,218,000 | +2.9% | 2,549,431 | 0.0% | 9.99% | +4.1% | |
| UTHR | UNITED THERAPEUTICS CORP DEL | $207,835,000 | +13.0% | 1,625,234 | 0.0% | 8.40% | +14.3% | |
| STAA | STAAR SURGICAL CO | $169,035,000 | +54.8% | 3,521,565 | 0.0% | 6.83% | +56.6% | |
| ALXN | Buy | ALEXION PHARMACEUTICALS INC | $166,840,000 | +13.3% | 1,200,201 | +1.2% | 6.74% | +14.6% |
| CLVS | Buy | CLOVIS ONCOLOGY INC | $153,342,000 | -32.2% | 5,221,026 | +5.0% | 6.20% | -31.4% |
| INSM | Buy | INSMED INC | $148,764,000 | -13.1% | 7,357,283 | +1.7% | 6.01% | -12.1% |
| SAGE | Buy | SAGE THERAPEUTICS INC | $118,703,000 | -8.9% | 840,372 | +0.9% | 4.80% | -7.9% |
| IMMU | Buy | IMMUNOMEDICS INC | $104,437,000 | -8.1% | 5,013,764 | +4.4% | 4.22% | -7.1% |
| VNDA | VANDA PHARMACEUTICALS INC | $95,373,000 | +20.5% | 4,155,670 | 0.0% | 3.86% | +21.8% | |
| WMGI | WRIGHT MED GROUP N V | $80,025,000 | +11.8% | 2,757,587 | 0.0% | 3.24% | +13.1% | |
| KPTI | KARYOPHARM THERAPEUTICS INC | $79,416,000 | +0.2% | 4,663,324 | 0.0% | 3.21% | +1.4% | |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $76,967,000 | -20.1% | 6,366,147 | +3.2% | 3.11% | -19.2% |
| EPZM | EPIZYME INC | $73,205,000 | -21.8% | 6,906,158 | 0.0% | 2.96% | -20.9% | |
| AMAG | Buy | AMAG PHARMACEUTICALS INC | $67,610,000 | +3.8% | 3,380,506 | +1.2% | 2.73% | +5.0% |
| ALGN | Sell | ALIGN TECHNOLOGY INC | $57,825,000 | -8.4% | 147,807 | -19.9% | 2.34% | -7.4% |
| MNTA | MOMENTA PHARMACEUTICALS INC | $48,222,000 | +28.6% | 1,833,532 | 0.0% | 1.95% | +30.1% | |
| CELG | Buy | CELGENE CORP | $38,415,000 | +22.5% | 429,267 | +8.7% | 1.55% | +23.9% |
| AIMT | AIMMUNE THERAPEUTICS INC | $37,694,000 | +1.5% | 1,381,759 | 0.0% | 1.52% | +2.6% | |
| ACAD | Buy | ACADIA PHARMACEUTICALS INC | $34,964,000 | +38.7% | 1,684,180 | +2.0% | 1.41% | +40.3% |
| SHPG | Buy | SHIRE PLCsponsored adr | $34,938,000 | +8.3% | 192,738 | +0.8% | 1.41% | +9.5% |
| ALDR | ALDER BIOPHARMACEUTICALS INC | $30,854,000 | +5.4% | 1,853,101 | 0.0% | 1.25% | +6.6% | |
| EXAS | EXACT SCIENCES CORP | $24,727,000 | +32.0% | 313,320 | 0.0% | 1.00% | +33.4% | |
| PRTA | PROTHENA CORP PLC | $14,431,000 | -10.3% | 1,103,325 | 0.0% | 0.58% | -9.3% | |
| GILD | GILEAD SCIENCES INC | $13,581,000 | +9.0% | 175,900 | 0.0% | 0.55% | +10.2% | |
| RIGL | RIGEL PHARMACEUTICALS INC | $12,731,000 | +13.4% | 3,966,087 | 0.0% | 0.52% | +14.7% | |
| DRNA | DICERNA PHARMACEUTICALS INC | $7,644,000 | +24.6% | 500,913 | 0.0% | 0.31% | +26.1% | |
| ALIM | ALIMERA SCIENCES INC | $2,954,000 | +0.2% | 3,013,793 | 0.0% | 0.12% | +0.8% | |
| SNSS | SUNESIS PHARMACEUTICALS INC | $2,325,000 | -5.6% | 1,162,473 | 0.0% | 0.09% | -4.1% | |
| ZGNX | ZOGENIX INC | $1,463,000 | +12.2% | 29,500 | 0.0% | 0.06% | +13.5% | |
| CYTK | CYTOKINETICS INC | $1,218,000 | +18.6% | 123,686 | 0.0% | 0.05% | +19.5% | |
| TRVN | TREVENA INC | $724,000 | +47.5% | 341,300 | 0.0% | 0.03% | +45.0% | |
| IDRA | New | IDERA PHARMACEUTICALS INC | $686,000 | – | 77,044 | +100.0% | 0.03% | – |
| SPHS | SOPHIRIS BIO INC | $689,000 | -0.7% | 247,000 | 0.0% | 0.03% | 0.0% | |
| MLNT | MELINTA THERAPEUTICS INC | $200,000 | -37.9% | 50,689 | 0.0% | 0.01% | -38.5% | |
| HSGX | HISTOGENICS CORP | $165,000 | -78.2% | 302,922 | 0.0% | 0.01% | -76.7% | |
| IDRA | Exit | IDERA PHARMACEUTICALS INC | $0 | – | -616,355 | -100.0% | -0.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Biomarin Pharmaceuticals, Inc | 42 | Q3 2023 | 16.6% |
| UNITED THERAPEUTICS CORP DEL | 42 | Q3 2023 | 15.3% |
| INSMED INC | 42 | Q3 2023 | 14.1% |
| STAAR Surgical Company | 42 | Q3 2023 | 11.8% |
| AMICUS THERAPEUTICS INC | 42 | Q3 2023 | 12.1% |
| VANDA PHARMACEUTICALS INC | 42 | Q3 2023 | 5.8% |
| PROTHENA CORP PLC | 42 | Q3 2023 | 9.1% |
| CYTOKINETICS INC | 40 | Q3 2023 | 0.4% |
| ALIGN TECHNOLOGY INC | 39 | Q3 2023 | 2.5% |
| ABIOMED INC | 38 | Q3 2022 | 17.1% |
View Palo Alto Investors LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ALIMERA SCIENCES INCSold out | April 03, 2023 | 0 | 0.0% |
| Epizyme, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| INSMED Inc | February 14, 2023 | 5,871,291 | 4.3% |
| Vanda Pharmaceuticals Inc. | February 14, 2023 | 1,087,064 | 1.4% |
| ALIMERA SCIENCES INC | February 14, 2022 | 802,423 | 11.6% |
| Clovis Oncology, Inc. | February 14, 2022 | 3,997,826 | 3.1% |
| STAAR SURGICAL CO | February 14, 2022 | 1,140,511 | 2.4% |
| Aimmune Therapeutics, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| AMAG PHARMACEUTICALS, INC.Sold out | February 16, 2021 | 0 | 0.0% |
| ALIMERA SCIENCES INC | February 14, 2020 | 802,424 | 16.2% |
View Palo Alto Investors LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-04-03 |
| 4 | 2023-03-28 |
View Palo Alto Investors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.